Dr. Adi Zuloff-Shani

(Part four of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction Next-Generation Psychedelics, MEAI - How And Why, An Israeli Scientist Explains Next-Generation Psychedelics, MEAI - What And When Clearmind...

(Part three of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction Next-Generation Psychedelics, MEAI - How And Why, An Israeli Scientist Explains MEAI is a potent synthetic molecule essentially developed in the...

(This is part two of a four-part series) Check out part one in the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction A compound developed by Israeli psychedelics company Clearmind Medicine (NASDAQ: CMND) would act by providing a similar feeling to...

(Part one of a four-part series) Increasing evidence of psychedelics’ potential for benefiting both mental and physical health conditions are moving biotech companies and scientists in the sector to major innovative heights. Psychedelic science is growing in terms of treatment specificity, as...

SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, has started the process of preparing for an Investigational New Drug Application (“IND”) with the U.S. Food and Drug...

India's Office of the Controller-General of Patents, Designs and Trademarks granted approval for a new compound created by the biotech company Clearmind Medicine Inc. (OTC Pink: CMNDF). Clearmind, whose work focuses on the discovery and development of novel psychedelic-derived therapeutics to...

The meeting, which took place on May 18 between the psychedelic pharmaceutical biotech company Clearmind Medicine Inc. (CMNDF) and the US Food and Drug Administration marks the completion the pre-IND New Drug Application stage. This will allow Clearmind to move forward in the...

Psychedelics biotech company Clearmind Medicine Inc. (OTC Pink: CMNDF) has published information pertaining to the safety and efficacy of its flagship molecule, called MEAI or CMND-100, after its pre-IND meeting with the Food and Drug Administration on Wednesday. MEAI is a proprietary psychedelic...